Why Real-World Evidence Matters for Indian Healthcare

Why Real-World Evidence Matters for Indian Healthcare

Introduction

Indian healthcare is at a defining crossroads. With a population of over 1.4 billion people spread across geographically diverse states, culturally distinct communities, and vastly different socioeconomic settings, the evidence base that drives clinical and policy decisions must reflect this reality. Yet for decades, the dominant framework for evaluating drugs, devices, and interventions has been the randomized controlled trial conducted in controlled environments, often in Western countries, with populations that bear little resemblance to the average Indian patient.

This is precisely where real-world evidence steps in as a necessary and powerful complement. Real-world evidence, commonly referred to as RWE, is derived from data collected outside the boundaries of traditional clinical trials. It draws from electronic health records, insurance claims data, patient registries, pharmacovigilance systems, and even digital health platforms. When applied thoughtfully to India's unique health landscape, real-world evidence has the potential to reshape how doctors make clinical decisions, how regulators approve and monitor therapies, and how policymakers design interventions that genuinely serve the Indian population.

Understanding Real-World Evidence and Its Foundations

Real-world evidence is not a new concept in global medicine, but it is gaining unprecedented attention in India as the country scales up its digital health infrastructure. To understand why it matters, it is important to distinguish between two closely related terms: real-world data and real-world evidence.

Real-world data refers to the raw, routinely collected health information generated in everyday clinical practice. This includes data from hospital information systems, outpatient records, diagnostic laboratory outputs, wearable health devices, and community health worker reports. Real-world evidence is the clinical evidence that is generated by analyzing this data to answer specific questions about treatment effectiveness, safety, disease burden, or population health trends.

The distinction is critical because data alone does not constitute evidence. It is the rigorous analysis, contextual interpretation, and methodological discipline applied to real-world data that produces insights capable of informing meaningful decisions in Indian healthcare.

In India, the momentum behind real-world evidence has been accelerated by the Ayushman Bharat Digital Mission, which seeks to create a unified digital health ecosystem through ABHA identity numbers, linked health records, and interoperable health data systems. This infrastructure creates, for the first time in India's history, the foundation for large-scale real-world data collection that can meaningfully support evidence generation at a national scale.

Why Randomized Controlled Trials Alone Are Not Enough for India

Randomized controlled trials have long been considered the gold standard for evaluating the safety and efficacy of medical interventions. However, their limitations become particularly pronounced in the Indian context.

Most pivotal clinical trials that form the basis of drug approvals by global regulators are conducted in North America, Europe, or in highly selected populations that exclude older adults, pregnant women, people with multiple comorbidities, and patients from low-resource settings. When these drugs enter the Indian market, clinicians are applying evidence generated in populations with different genetic profiles, different disease presentations, different dietary habits, and different levels of access to supportive care.

India has one of the highest burdens of tuberculosis, diabetes, cardiovascular disease, and chronic kidney disease in the world. The way these conditions present, progress, and respond to therapy in an Indian patient managed in a district hospital in Uttar Pradesh or a primary health centre in rural Odisha is fundamentally different from how the same condition might present in a patient enrolled in a trial in Boston or Berlin.

Furthermore, Indian patients often present with polypharmacy, meaning they are taking multiple medications simultaneously, including over-the-counter drugs, herbal preparations, and Ayurvedic formulations. The interactions between these agents and prescription drugs are rarely studied in trial settings but show up consistently in real-world clinical practice. Real-world evidence is the only systematic mechanism through which these interactions can be identified, studied, and addressed.

Key Areas Where Real-World Evidence Transforms Indian Healthcare

Real-world evidence contributes to Indian healthcare across several interconnected domains.

Drug Safety and Pharmacovigilance

India's Pharmacovigilance Programme of India, operated under the coordination of the Indian Pharmacopoeia Commission, collects adverse drug reaction data from across the country. This programme is a real-world evidence system. When a drug approved on the basis of a clinical trial causes an unexpected adverse reaction in a subset of Indian patients, it is the pharmacovigilance network that captures this signal. Real-world evidence allows regulators and clinicians to detect safety signals that were invisible during controlled trials, leading to timely label updates, prescribing alerts, and in some cases, market withdrawals that protect patient safety.

Treatment Effectiveness in Routine Practice

There is a well-documented gap between efficacy, which is how a drug performs under ideal trial conditions, and effectiveness, which is how it performs in everyday clinical practice. For Indian healthcare, this gap is wider than in most other countries because of the diversity of clinical settings, the heterogeneity of patient populations, and the variability in adherence to prescribed treatments. Real-world evidence studies conducted in Indian hospitals and clinics can reveal which treatments are actually working in routine practice, helping clinicians make more informed prescribing decisions for their specific patient populations.

Disease Burden Estimation and Public Health Planning

Accurate disease burden data is the foundation of rational public health policy. India has historically relied on periodic surveys and modelling studies to estimate the burden of non-communicable and infectious diseases. Real-world data from hospital information systems, insurance claims under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, and state health records can now provide more granular, timely, and geographically specific data on disease burden. This has direct implications for how the Ministry of Health and Family Welfare allocates resources, designs national health programmes, and evaluates the impact of existing interventions.

Health Technology Assessment

The Health Technology Assessment in India initiative, coordinated through HTAIn under the Department of Health Research, uses evidence to evaluate the clinical and economic value of health technologies for inclusion in public benefit packages. Real-world evidence plays an essential role here by providing cost-effectiveness data that reflects actual healthcare costs, utilisation patterns, and outcomes in the Indian system rather than estimates derived from foreign studies.

Regulatory Decision-Making

The Central Drugs Standard Control Organisation has been actively developing frameworks to incorporate real-world evidence in post-marketing regulatory decisions. For drugs approved through accelerated pathways or for conditions with limited clinical trial data, post-market real-world studies serve as a critical mechanism for confirming benefit-risk profiles in the Indian population.

Challenges in Building a Robust Real-World Evidence Ecosystem in India

Despite its promise, the real-world evidence ecosystem in India faces significant structural and systemic challenges that must be addressed thoughtfully.

Data quality remains a fundamental concern. Much of the healthcare data generated in India exists in fragmented silos, is recorded inconsistently, or is maintained in paper-based formats that are not amenable to digital analysis. Even in digitised hospitals, data entry practices vary widely, diagnostic coding is often incomplete, and follow-up data is frequently missing because patients shift between public and private providers without continuity of records.

Privacy and data governance are equally pressing issues. India's Digital Personal Data Protection Act, enacted in 2023, creates a legal framework for handling personal data, but the specific guidance for health data research is still evolving. Researchers and institutions need clarity on consent frameworks, data anonymisation standards, and the permissible use of health data for secondary research purposes.

Methodological expertise in real-world evidence study design is limited across Indian academic medical centres and research institutions. Unlike randomized trials, where established protocols guide design and conduct, real-world evidence studies require sophisticated knowledge of causal inference methods, bias control techniques, and statistical approaches suited to observational data. Building this capacity within Indian institutions requires deliberate investment in training, mentorship, and collaborative research infrastructure.

Representation gaps also persist. Data generated from tertiary care hospitals in metropolitan cities does not represent the experience of patients in rural areas, smaller towns, or those receiving care through the public sector. For real-world evidence to be meaningful for Indian healthcare policy, the data infrastructure must deliberately extend to district hospitals, community health centres, and Ayushman Bharat Health and Wellness Centres.

The Role of Medical Communities and Healthcare Platforms in Advancing Real-World Evidence

Physicians, medical associations, and healthcare communities have an indispensable role in the real-world evidence ecosystem. Clinicians are not merely consumers of evidence; they are the primary generators of real-world data through every consultation they document, every prescription they record, and every adverse event they report to the pharmacovigilance system.

Medical associations across India have the unique ability to organize clinician networks around structured data collection for specific disease areas, creating condition-specific registries that can generate high-quality, systematically collected real-world data. When cardiologists, diabetologists, oncologists, or neurologists come together through their professional bodies to agree on standardized data collection formats and outcome definitions, the result is evidence that is far more actionable and credible than data collected ad hoc.

Platforms that connect doctors and healthcare communities serve as important enablers in this process. They facilitate knowledge sharing about evidence generation methods, highlight best practices from institutions where real-world evidence research is already underway, and create visibility for physician-led research that often goes unrecognized in mainstream academic publication channels. A well-connected doctor community is a more evidence-literate community, and evidence literacy among practising physicians is one of the most important drivers of better real-world evidence utilization in clinical practice.

Building India's Future on Real-World Evidence

The future of Indian healthcare policy and clinical practice will depend significantly on whether the country can build a mature, trustworthy, and inclusive real-world evidence ecosystem. Several steps are essential to achieving this.

First, the Ayushman Bharat Digital Mission must be leveraged not merely as an administrative health identity system but as a research infrastructure that enables longitudinal tracking of patient outcomes across providers and geographies.

Second, ICMR and the Department of Health Research should establish clear national guidelines for real-world evidence study design, data governance, and ethical review processes, making it easier for researchers across institutions to initiate and conduct rigorous real-world studies.

Third, medical education in India must incorporate training in epidemiology, evidence appraisal, and real-world study methods so that future generations of clinicians are equipped to both generate and interpret real-world evidence.

Fourth, collaboration between academic medical centres, the pharmaceutical industry, regulatory agencies, and patient communities is essential. Each of these stakeholders brings different data assets, analytical capabilities, and research interests to the table, and their collaboration can produce evidence that is richer and more actionable than any single-sector effort.

India is uniquely positioned to become a global leader in real-world evidence generation, given the scale of its health system, the diversity of its population, and the ambition of its digital health agenda. Realizing this potential requires commitment from clinicians, policymakers, researchers, and healthcare institutions to treat real-world evidence not as an afterthought but as a central pillar of evidence-based healthcare.

Conclusion

Real-world evidence represents a fundamental shift in how Indian healthcare can understand, evaluate, and improve the treatments and policies that affect over a billion people. By capturing the lived clinical experience of patients across diverse geographies, demographics, and disease states, real-world evidence fills the gaps that controlled trials inevitably leave behind. For India, with its extraordinary complexity and unmet health needs, the systematic development and utilization of real-world evidence is not merely an academic priority but a moral and public health imperative. The doctors, associations, and healthcare institutions that invest in building this evidence base today are laying the foundation for a more equitable, effective, and responsive healthcare system for generations to come.

Frequently Asked Questions

Q1: What is real-world evidence in the context of Indian healthcare?

Real-world evidence in Indian healthcare refers to clinical evidence generated from the analysis of real-world data collected outside traditional randomized trials. This includes data from electronic health records, insurance claims, patient registries, and pharmacovigilance systems used to evaluate how treatments perform in routine Indian clinical practice.

Q2: How is real-world evidence different from randomized controlled trial evidence?

Randomized controlled trials evaluate how a drug or intervention performs under carefully controlled conditions with selected patient populations. Real-world evidence reflects how the same drug or intervention performs in everyday clinical settings, including in patients with multiple comorbidities, varying adherence levels, and diverse genetic and lifestyle profiles, such as those commonly seen in Indian healthcare settings.

Q3: What role does the Ayushman Bharat Digital Mission play in real-world evidence generation?

The Ayushman Bharat Digital Mission creates a digital health infrastructure that enables the longitudinal tracking of patient health records across providers and geographies in India. This infrastructure forms the foundational data layer needed to support large-scale real-world evidence studies that can inform clinical practice and national health policy.

Q4: What are the main challenges facing real-world evidence research in India?

The main challenges include fragmented and inconsistently recorded health data, limited methodological expertise in real-world study design among Indian researchers, evolving data privacy regulations under the Digital Personal Data Protection Act, and under-representation of rural and lower-income populations in existing health datasets.

Q5: How can Indian doctors and medical associations contribute to real-world evidence?

Indian doctors contribute to real-world evidence by systematically documenting clinical encounters, reporting adverse drug reactions to the Pharmacovigilance Programme of India, and participating in disease-specific registries. Medical associations can organize clinician networks around standardized data collection to generate high-quality, specialty-specific real-world evidence.

Resources

1. Indian Council of Medical Research (ICMR): Guidelines, publications, and research frameworks on evidence-based medicine and health data research in India.
2. World Health Organization India Country Office: Reports and technical documents on health systems strengthening, disease burden estimation, and evidence use in policy for the South-East Asia region.
3. Ayushman Bharat Digital Mission (ABDM): Official documentation on India's national digital health ecosystem, ABHA identity systems, and health data interoperability frameworks.
4. Health Technology Assessment India (HTAIn): Resources on health technology appraisal methods, evidence submission guidelines, and published assessments informing India's public benefit packages.
5. Pharmacovigilance Programme of India, Indian Pharmacopoeia Commission: Guidance on adverse drug reaction reporting, real-world drug safety monitoring, and national pharmacovigilance frameworks.

Interlinking Keywords

Real-world evidence India, RWE clinical practice, pharmacovigilance India, Ayushman Bharat Digital Mission, health technology assessment India, evidence-based medicine India, ICMR research guidelines, Indian healthcare policy, digital health data India, post-market drug surveillance

Last reviewed by: 

Dr. Manthan Tripathi, HealthVoice Editorial and Medical Advisory Team, October 24, 2026.

Disclaimer

The information presented in this article is intended for educational and informational purposes only. It does not constitute medical advice, clinical guidance, or a substitute for professional medical consultation. Readers are advised to consult qualified healthcare professionals for any medical decisions. HealthVoice does not endorse any specific drug, therapy, device, or clinical intervention mentioned in this article. All references to regulatory bodies, government schemes, and research institutions are for informational context only.

#RealWorldEvidence #EvidenceBasedHealthcare